Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02238483 · ClinicalTrials.gov registry record · Phase 2
A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 213
- Enrollment target
NCT02238483 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 213 participants.
The verdict
NCT02238483, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 213 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether AZD7624 can reduce acute Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients on COPD maintenance therapy with a history of frequent acute exacerbations.
Interventions
- DRUG Placebo
- DRUG AZD7624 1.0 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2014-10-28 |
| Est. Completion | 2016-04-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02238483
The ClinicalTrials.gov registry entry for NCT02238483 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02238483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02238483 about?
NCT02238483 is a clinical study titled "A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy". The purpose of this study is to determine whether AZD7624 can reduce acute Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients on COPD maintenance therapy with a history of frequent acute exacerbations.
What is the current status of trial NCT02238483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 213 participants. The study started on 2014-10-28. Estimated completion is 2016-04-04.
What interventions are being tested in trial NCT02238483?
The interventions under investigation include: Placebo (DRUG), AZD7624 1.0 mg (DRUG).
Who is sponsoring clinical trial NCT02238483?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.